Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Quantin

Showing results (41-50 of 82) with videos related to

Pageof 9
Sort By:
Cancers|November 9, 2024
Optimizing Treatment Strategies for <i>Egfr</i>-Mutated Non-Small-Cell Lung Cancer Treated with Osimertinib: Real-World Outcomes and InsightsQuentin Dominique Thomas, Nicolas Girard, Lise Bosquet, et al.
Cancers|January 11, 2022
Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort ExperienceTina Lamy, Bastien Cabarrou, David Planchard, et al.
European Archives of Psychiatry and Clinical Neuroscience|March 13, 2014
Smoking behavior characteristics of non-selected smokers with childhood attention-deficit/hyperactivity disorder (AD/HD) history: a systematic review and meta-analysisGuillaume Fond, Anderson Loundou, Sebastien Guillaume, et al.
Journal of Neurosurgery|January 19, 2024
Prognostic impact of the number and total tumor burden of secondary cerebral lesions in patients with resected brain metastases of non-small cell lung cancersSidonie Sauvageot, Caroline Mollevi, Quentin D Thomas, et al.
Lung Cancer (Amsterdam, Netherlands)|March 4, 2022
Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trialJarushka Naidoo, Johan F Vansteenkiste, Corinne Faivre-Finn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2019
Ultra-sensitive <i>EGFR</i> <sup>T790M</sup> Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring <i>EGFR</i> <sup>del19</sup> Mutations and Treated with First-generation TKIsJulie A Vendrell, Julien Mazieres, Romain Senal, et al.
Cancer Immunology, Immunotherapy : CII|May 26, 2022
Pulmonary hypertension reported with immune checkpoint inhibitors: a pharmacovigilance studyPascale Palassin, Alexandre T J Maria, Chayma Ladhari, et al.
Cancers|July 24, 2021
Generation and Characterization of a New Preclinical Mouse Model of EGFR-Driven Lung Cancer with MET-Induced Osimertinib ResistanceMaicol Mancini, Quentin-Dominique Thomas, Sylvia Bourdel, et al.
Lung Cancer (Amsterdam, Netherlands)|November 14, 2021
Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohortNicolas Girard, Maurice Perol, Gaëtane Simon, et al.
Cancer Immunology, Immunotherapy : CII|February 12, 2026
Rituximab for severe immune checkpoint inhibitor-related adverse events: a multicenter case seriesStéphanie Hermabessiere, Benjamin Jauzelon, Steven Marmain, et al.
Pageof 9

Showing results (41-50 of 82) with videos related to

Sort By:
Pageof 9
Cancers|November 9, 2024
Optimizing Treatment Strategies for <i>Egfr</i>-Mutated Non-Small-Cell Lung Cancer Treated with Osimertinib: Real-World Outcomes and InsightsQuentin Dominique Thomas, Nicolas Girard, Lise Bosquet, et al.
Cancers|January 11, 2022
Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort ExperienceTina Lamy, Bastien Cabarrou, David Planchard, et al.
European Archives of Psychiatry and Clinical Neuroscience|March 13, 2014
Smoking behavior characteristics of non-selected smokers with childhood attention-deficit/hyperactivity disorder (AD/HD) history: a systematic review and meta-analysisGuillaume Fond, Anderson Loundou, Sebastien Guillaume, et al.
Journal of Neurosurgery|January 19, 2024
Prognostic impact of the number and total tumor burden of secondary cerebral lesions in patients with resected brain metastases of non-small cell lung cancersSidonie Sauvageot, Caroline Mollevi, Quentin D Thomas, et al.
Lung Cancer (Amsterdam, Netherlands)|March 4, 2022
Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trialJarushka Naidoo, Johan F Vansteenkiste, Corinne Faivre-Finn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2019
Ultra-sensitive <i>EGFR</i> <sup>T790M</sup> Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring <i>EGFR</i> <sup>del19</sup> Mutations and Treated with First-generation TKIsJulie A Vendrell, Julien Mazieres, Romain Senal, et al.
Cancer Immunology, Immunotherapy : CII|May 26, 2022
Pulmonary hypertension reported with immune checkpoint inhibitors: a pharmacovigilance studyPascale Palassin, Alexandre T J Maria, Chayma Ladhari, et al.
Cancers|July 24, 2021
Generation and Characterization of a New Preclinical Mouse Model of EGFR-Driven Lung Cancer with MET-Induced Osimertinib ResistanceMaicol Mancini, Quentin-Dominique Thomas, Sylvia Bourdel, et al.
Lung Cancer (Amsterdam, Netherlands)|November 14, 2021
Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohortNicolas Girard, Maurice Perol, Gaëtane Simon, et al.
Cancer Immunology, Immunotherapy : CII|February 12, 2026
Rituximab for severe immune checkpoint inhibitor-related adverse events: a multicenter case seriesStéphanie Hermabessiere, Benjamin Jauzelon, Steven Marmain, et al.
Pageof 9